Streetbeat News

Regulatory

ATNF

180 Life Sciences Corp. (NASDAQ:ATNF) has been granted an extension by the Nasdaq Listing Qualifications Panel to regain compliance with Nasdaq's continued listing requirements. The company has until September 20, 2024, to meet the Equity Rule and maintain its listing on Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:06 pm

ATRC

AtriCure has received approval from the National Medical Products Administration (NMPA) to sell its AtriClip devices in China. This regulatory milestone opens up a significant market for the company, potentially boosting its revenues and market presence in the Asia-Pacific region.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:05 pm

ADIL

Adial Pharmaceuticals (NASDAQ:ADIL) has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. The study, which began in June 2024, is expected to conclude in Q4 2024, with topline results anticipated in the same quarter. The results will inform the design of a Phase 3 Clinical Trial.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 12:00 pm

MESO

Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:59 am

MESO

The FDA has accepted Mesoblast's Biologics License Application (BLA) for Ryoncil, a treatment for children with steroid-refractory acute graft-versus-host disease. This is a significant milestone for Mesoblast as it moves closer to potentially bringing Ryoncil to market.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:56 am

LI

TSLA

XIACF

XIACY

XPEV

Xiaomi has received regulatory clearance to mass-produce electric vehicles independently, marking a significant milestone in its EV ambitions. Despite production bottlenecks and quality issues, Xiaomi's SU7 model has seen strong demand. The company plans to launch more models and increase its delivery targets. However, Xiaomi faces challenges such as anti-dumping tariffs in Europe and slowing demand in China.

Portfolio Pulse from The Bamboo Works

July 23, 2024 | 11:55 am

ANIX

Anixa Biosciences Inc (NASDAQ:ANIX) announced FDA approval for an individual patient trial application for its ovarian cancer CAR-T therapy. The trial, conducted in collaboration with Moffit Cancer Center, has shown promising early results. Additionally, Anixa's Board of Directors has authorized a $5 million share repurchase program, indicating confidence in the company's valuation.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 11:45 am

ANIX

Anixa Biosciences has announced FDA approval of an Individual Patient IND for its ovarian cancer CAR-T therapy.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:45 am

DKNG

DraftKings plans to launch mobile sports betting in Washington D.C., pending licensure and regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:33 am

GM

GM's Cruise is abandoning its plans for the pedal-less Origin autonomous vehicle and will focus on the next-generation Chevrolet Bolt for autonomous driving. This shift is due to regulatory uncertainties and cost optimization. Cruise reported a significant operating loss and restructuring costs for the first half of 2024.

Portfolio Pulse from Anan Ashraf

July 23, 2024 | 11:28 am